Early Diagnosis of Childhood Multiple Endocrine Neoplasia Type 2 (MEN 2)

Multiple Endocrine Neoplasia type 2 (MEN 2) is a rare, inherited condition that can lead to tumors in various endocrine glands. It’s crucial to understand that while MEN 2 can affect individuals of all ages, early diagnosis in childhood is particularly vital for effective management and improved outcomes. This condition primarily impacts the thyroid and parathyroid glands, and adrenal glands, but can also involve other tissues. Genetic testing plays a key role in identifying the gene changes responsible for MEN 2, allowing healthcare providers to intervene proactively and address potential health issues in children.

MEN 2 is passed down through families, meaning a parent with the altered gene has a 50% chance of passing it on to each child. Understanding the types of MEN 2 and recognizing the signs early in childhood can make a significant difference in a child’s health journey.

Types of MEN 2 in Children

There are two main types of MEN 2, both of which can be diagnosed in childhood:

MEN 2A: Also known as classical MEN 2A or Sipple syndrome, this is the more common form. In children, MEN 2A typically involves medullary thyroid cancer (MTC) and noncancerous tumors of the parathyroid glands (hyperparathyroidism) and adrenal glands (pheochromocytoma).
MEN 2B: This is a rarer and often more aggressive type of MEN 2. Children with MEN 2B develop medullary thyroid cancer and pheochromocytoma. Uniquely, MEN 2B also causes noncancerous tumors called neuromas on the lips, tongue, and digestive tract. Parathyroid gland issues are generally not seen in MEN 2B.

Recognizing Symptoms of MEN 2 in Children

Symptoms of MEN 2 in children depend on the type of tumors present and which glands are affected. It’s important for parents and caregivers to be aware of potential signs, especially if there is a family history of MEN 2 or related conditions.

MEN 2B Symptoms in Children: A Distinct Presentation

Children with MEN 2B often have a distinctive appearance that can aid in early diagnosis. They may exhibit:

Neuromas: Small bumps or nodules on the lips, tongue, and eyelids. These are tumors of nerve tissue and are a hallmark of MEN 2B.
Physical Build: Children with MEN 2B tend to be taller and thinner than their peers, with longer limbs.

Beyond these unique features, symptoms of MEN 2 in children can be related to specific tumor types:

Medullary Thyroid Cancer (MTC):

Neck Lump: A noticeable lump or swelling in the neck area is a primary sign.
Swallowing or Breathing Difficulties: As the tumor grows, it can press on the trachea or esophagus, causing difficulty swallowing or breathing.
Hoarseness: Changes in voice, such as persistent hoarseness.
Diarrhea: In some cases, MTC can produce hormones that lead to chronic diarrhea.

Hyperparathyroidism (in MEN 2A):

Muscle and Joint Pain: Elevated calcium levels due to overactive parathyroid glands can cause aches and pains.
Constipation: Digestive issues, including constipation.
Fatigue: Unexplained tiredness and lack of energy.
Memory Problems: Cognitive difficulties or memory issues.
Kidney Stones: Increased calcium in the urine can lead to kidney stone formation.

Pheochromocytoma (in both MEN 2A and MEN 2B):

High Blood Pressure: Sudden and persistent high blood pressure.
Rapid Heart Rate: Palpitations or a racing heart.
Anxiety: Feelings of nervousness or anxiety.
Headaches: Severe or frequent headaches.
Sweating: Excessive sweating.

It is important to note that some children with medullary thyroid cancer may not exhibit any noticeable symptoms initially. This underscores the importance of screening for children at risk.

The Critical Importance of Early Childhood Diagnosis

Early diagnosis of childhood MEN 2 is crucial for several reasons:

Preventing Metastasis of Medullary Thyroid Cancer: MTC, if left untreated, can spread to other parts of the body. Early detection and treatment significantly improve the prognosis.
Managing Hyperparathyroidism and Pheochromocytoma: Early diagnosis allows for timely management of parathyroid and adrenal tumors, preventing complications related to hormone imbalances.
Prophylactic Thyroidectomy: In many cases, especially for children with the RET gene mutation associated with MEN 2, a prophylactic thyroidectomy (preventive removal of the thyroid gland) is recommended in childhood to prevent or cure MTC.
Genetic Counseling and Family Screening: Diagnosis in a child allows for genetic counseling for the family and screening of other family members who may be at risk, enabling early intervention for them as well.

Diagnostic Process for Childhood MEN 2

If MEN 2 is suspected in a child, the diagnostic process typically involves:

Physical Examination: A thorough physical exam, looking for signs like neuromas in MEN 2B and assessing for neck lumps.
Family History: Gathering detailed family medical history, especially regarding thyroid cancer, hyperparathyroidism, pheochromocytoma, or MEN 2.
Genetic Testing: Blood test to analyze the RET gene. Identifying a specific RET mutation confirms the diagnosis of MEN 2. This is the most definitive diagnostic tool.
Blood and Urine Tests:
- Calcitonin Levels: To screen for medullary thyroid cancer. Elevated calcitonin levels can be an early indicator of MTC.
- Parathyroid Hormone (PTH) and Calcium Levels: To assess for hyperparathyroidism.
- Metanephrines and Catecholamines (urine and blood): To screen for pheochromocytoma.
Imaging Studies:
- Ultrasound of the Neck: To visualize the thyroid gland and detect nodules.
- CT Scans or MRI: May be used to further evaluate the thyroid, adrenal glands, or to check for metastasis if MTC is suspected.

Genetic Basis and Inheritance of MEN 2

MEN 2 is caused by mutations in the RET proto-oncogene. These mutations are inherited in an autosomal dominant pattern. This means that only one copy of the altered gene is needed to cause the condition. If a parent carries a RET mutation, each child has a 50% chance of inheriting it and developing MEN 2.

In some cases, a de novo mutation can occur, meaning the child is the first in the family to have the mutation. However, once the mutation is present, it can be passed on to future generations.

Potential Complications if Undiagnosed in Childhood

If MEN 2 remains undiagnosed and untreated in children, potential complications can arise from each type of tumor:

Metastatic Medullary Thyroid Cancer: Spread of thyroid cancer to lymph nodes and distant organs.
Severe Hyperparathyroidism: Leading to osteoporosis, kidney stones, and other health issues due to chronically high calcium levels.
Hypertensive Crises from Pheochromocytoma: Untreated pheochromocytomas can cause dangerous spikes in blood pressure, leading to stroke, heart attack, or even death.

Prevention and Screening Strategies in Childhood

For families with a known history of MEN 2, prevention and early detection are paramount:

Genetic Testing for At-Risk Children: Children with a parent who has MEN 2 should undergo genetic testing for RET mutations, ideally in early infancy.
Prophylactic Thyroidectomy Based on Genetic Risk: For children with specific high-risk RET mutations, prophylactic thyroidectomy is typically recommended, often before the age of 5, to prevent MTC. The timing is guided by the specific mutation and expert consensus guidelines.
Regular Screening: Even if genetic testing is negative but family history is suggestive, or if MEN 2 is suspected based on symptoms, regular blood and urine tests to monitor hormone levels and imaging studies may be recommended.

Early diagnosis of childhood MEN 2, coupled with proactive management strategies like genetic testing and prophylactic thyroidectomy, significantly improves the outlook for affected children, enabling them to live healthier lives. If you have concerns about MEN 2 in your child or family history, consulting with a healthcare provider experienced in endocrine disorders is essential.

References

Multiple endocrine neoplasia type 2. Cancer.net. https://www.cancer.net/cancer-types/multiple-endocrine-neoplasia-type-2. Accessed Aug. 28, 2022.
Lips CJ, et al. Classification and genetics of multiple endocrine neoplasia type 2. https://www.uptodate.com/contents/search. Accessed Aug. 8, 2022.
Lips CJ, et al. Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2. https://www.uptodate.com/contents/search. Accessed Aug. 8, 2022.
Lips CJ, et al. Approach to therapy in multiple endocrine neoplasia type 2. https://www.uptodate.com/contents/search. Accessed Aug. 8, 2022.
AskMayoExpert. Multiple endocrine neoplasia type 2. Mayo Clinic; 2022.
Kliegman RM, et al, eds. Multiple endocrine neoplasia syndromes. In: Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 22, 2022.
Multiple endocrine neoplasia, type 2A (MEN 2A). Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/multiple-endocrine-neoplasia-men-syndromes/multiple-endocrine-neoplasia,-type-2a-men-2a. Accessed Aug. 28, 2022.
Multiple endocrine neoplasia, type 2B (MEN 2B). Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/multiple-endocrine-neoplasia-men-syndromes/multiple-endocrine-neoplasia,-type-2b-men-2b. Accessed Aug. 28, 2022.
Childhood multiple endocrine neoplasia (MEN) syndromes treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/multiple-endocrine-neoplasia/patient-child-men-syndromes-treatment-pdq. Accessed Aug. 28, 2022.
Tuttle RM. Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging. https://www.uptodate.com/contents/search. Accessed Sept. 20, 2022.
Ami, T. Allscripts EPSi. Mayo Clinic. Oct. 3, 2022.